EXAS Exact Sciences Corp

Price (delayed)

$49.84

Market cap

$9.2B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.32

Enterprise value

$11.4B

Exact Sciences Corp. is a molecular diagnostics company with an initial focus on the early detection and prevention of colorectal cancer. Exact Sciences Corp. launched Cologuard in 2014, the first ...

Highlights
EXAS's gross profit is up by 16% year-on-year
EXAS's revenue is up by 15% year-on-year
Exact Sciences's EPS has soared by 55% YoY but it has decreased by 17% from the previous quarter
The company's net income has surged by 54% YoY but it fell by 18% QoQ
The company's quick ratio fell by 46% YoY and by 32% QoQ

Key stats

What are the main financial stats of EXAS
Market
Shares outstanding
184.53M
Market cap
$9.2B
Enterprise value
$11.4B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.89
Price to sales (P/S)
3.59
EV/EBIT
N/A
EV/EBITDA
348.04
EV/Sales
4.5
Earnings
Revenue
$2.53B
EBIT
-$206.18M
EBITDA
$32.77M
Free cash flow
-$20.46M
Per share
EPS
-$1.32
Free cash flow per share
-$0.11
Book value per share
$17.26
Revenue per share
$13.9
TBVPS
$11.75
Balance sheet
Total assets
$6.38B
Total liabilities
$3.24B
Debt
$2.56B
Equity
$3.13B
Working capital
$435.16M
Liquidity
Debt to equity
0.82
Current ratio
1.64
Quick ratio
1.3
Net debt/EBITDA
67.38
Margins
EBITDA margin
1.3%
Gross margin
73.7%
Net margin
-9.5%
Operating margin
-9.7%
Efficiency
Return on assets
-3.8%
Return on equity
-7.7%
Return on invested capital
-5.7%
Return on capital employed
-3.6%
Return on sales
-8.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXAS stock price

How has the Exact Sciences stock price performed over time
Intraday
-7.84%
1 week
-1.07%
1 month
-21.19%
1 year
-39.59%
YTD
-32.63%
QTD
-27.83%

Financial performance

How have Exact Sciences's revenue and profit performed over time
Revenue
$2.53B
Gross profit
$1.87B
Operating income
-$244.61M
Net income
-$240.23M
Gross margin
73.7%
Net margin
-9.5%
The company's net margin has surged by 60% YoY but it fell by 16% QoQ
The operating margin has surged by 57% year-on-year but it has declined by 13% since the previous quarter
The company's net income has surged by 54% YoY but it fell by 18% QoQ
The operating income has surged by 50% year-on-year but it has declined by 14% since the previous quarter

Growth

What is Exact Sciences's growth rate over time

Valuation

What is Exact Sciences stock price valuation
P/E
N/A
P/B
2.89
P/S
3.59
EV/EBIT
N/A
EV/EBITDA
348.04
EV/Sales
4.5
Exact Sciences's EPS has soared by 55% YoY but it has decreased by 17% from the previous quarter
The stock's price to book (P/B) is 51% less than its 5-year quarterly average of 5.9 and 34% less than its last 4 quarters average of 4.4
The company's equity rose by 2.4% YoY
EXAS's price to sales (P/S) is 62% less than its 5-year quarterly average of 9.4 and 37% less than its last 4 quarters average of 5.7
EXAS's revenue is up by 15% year-on-year

Efficiency

How efficient is Exact Sciences business performance
Exact Sciences's ROS has soared by 65% YoY but it has decreased by 11% from the previous quarter
The company's return on invested capital has surged by 58% YoY but it fell by 14% QoQ
EXAS's return on assets has surged by 54% year-on-year but it is down by 19% since the previous quarter
The ROE has soared by 54% YoY but it has contracted by 17% from the previous quarter

Dividends

What is EXAS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXAS.

Financial health

How did Exact Sciences financials performed over time
The total assets is 97% more than the total liabilities
The company's quick ratio fell by 46% YoY and by 32% QoQ
EXAS's current ratio is down by 45% YoY and by 29% QoQ
The company's debt is 18% lower than its equity
The company's equity rose by 2.4% YoY
EXAS's debt to equity is down by 2.4% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.